Janssen’s diabetes drug Invokana shows benefits in real-world study

Janssen has announced new real-world study data that demonstrates the effectiveness of its diabetes drug Invokana.

The new evidence, presented at the American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress, showed that people with type 2 diabetes treated with Invokana were as likely to achieve blood glucose control as those receiving injectable GLP-1 receptor agonists.

Patients on Invokana were also shown to be less likely to discontinue their medication or be prescribed a new antihyperglycaemic agent.

Data from real-world studies such as this reflect everyday clinical practice, meaning the findings generated by such research can help doctors to decide the best course of treatment for their patients.

Dr Paul Burton, vice-president for medical affairs at Janssen, said: "With this analysis, we are proud to expand the body of real-world evidence for Invokana and to further establish its benefits in everyday patient care."

The drug has been available in Europe for the treatment of type 2 diabetes since 2013.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.